Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
56 hedge funds and large institutions have $9.81M invested in Genocea Biosciences, Inc. in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
10% less funds holding
Funds holding: 62 → 56 (-6)
33% less capital invested
Capital invested by funds: $14.6M → $9.81M (-$4.75M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$216K |
| 2 |
Millennium Management
New York
|
+$157K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$139K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$51.1K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
-$844K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$715K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$529K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$220K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$154K |
GNCA Hedge Fund Activity: Q4 2017 in Review
56 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q4 2017, worth a combined $9.81M — down 33% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of GNCA and 9 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 15 added.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $216K. The largest seller was Axa, exiting entirely with an estimated $844K sold.
- 56 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q4 2017, down from 62 in Q3 2017.
- Funds reported $9.81M of Genocea Biosciences, Inc. stock for Q4 2017, down 33% quarter-over-quarter.
- 9 funds opened new Genocea Biosciences, Inc. positions in Q4 2017 and 15 closed out, a net change of -6 holders.
- The largest Genocea Biosciences, Inc. buyer in Q4 2017 was A.R.T. Advisors, an estimated $216K added.
- The largest Genocea Biosciences, Inc. seller in Q4 2017 was Axa, an estimated $844K sold.
Based on aggregated 13F filings for Q4 2017.